Additional key phrases: pharmacokinetics; absorption; ileostomy TABLE 1. Event summary: transplant at the age of 54 years Tx =Transplant; TV =truncal vagotomy; ICA =ileocolic anastomosis; IRA = ileo-rectal anastomosis.
The role of cyclosporin A (CyA) in the prevention of rejection in renal transplant recipients is well established.' Administration using the original liquid formulation has largely been abandoned because of its unpalatable taste and difficulties with exact dosage in visually impaired patients.
Most centres now use CyA in soft gelatine capsules which give similar absorption, bioavailability and pharmacokinetic parameters as the liquid formulation.t-' The bioavailability of CyA is, however, related to the destruction of the capsule within the stomach and upper gastrointestinal tract. We report a renal transplant recipient with a partial gastrectomy and ileostomy, whose whole blood CyA concentrations improved only when he was switched from CyA capsules to a liquid form. The case also emphasizes the rapid absorption of CyA which occurs predominantly in the upper gastrointestinal tract. 4 dilatation, due to clostridium difficile colitis and required partial colectomy and ileo-colic anastomosis. Eighteen months later a further episode of toxic dilatation developed due to the same organism, after antibiotic prophylaxis for a plastic surgical procedure. Further colonic resection, ileo-rectal anastomosis and proximal loop ileostomy was performed. This was complicated by a jejune-cutaneous small bowel fistula following the closure of ileostomy. This fistula was treated, a year later, by a planned higher ileostomy and resection and end-to-end anastomosis of the fistula-containing small bowel. Thus, the patient finished with a bypass of his duodenum and proximal jejunum, and with a high ileal stoma.
CASE REPORT

Event
Immunosuppression
The patient received a single oral dose of CyA (7' 5 mg/kg) 1 h before transplantation. Postoperatively he was treated with cyclosporin monotherapy: 5 mg/kg/day CyA was given intravenously for 2 days post transplant, then oral (capsule) CyA (14 mg/kg/day) was commenced. This dosage maintained a pre-dose CyA blood concentration of 336 ng/mL measured by HPLC. 5 He developed jaundice due to suspected CyA hepato-toxicity, following the first laparotomy and the immunosuppression was changed to triple therapy: CyA 5 mg/kg/day, azathioprine 2 mg/kg/day and prednisolone 20 mg/day. On this regime, the blood CyA concentration was 140 ng/mL. He continued on triple therapy from 1-18 months post transplantation. There were no rejection episodes and the serum creatinine concentration at 18 months was 120 JLmoIlL. At this stage the patient developed the small intestinal fistula and was changed back to CyA monotherapy, since prednisolone was considered to be a contributory factor in the persistent non-healing of the intestinal fistula. Routine monitoring revealed a marked and persistent fall in whole blood CyA concentrations to < 50 ng/mL from the time that the fistula developed, despite an increase in the daily dose of CyA capsules to 14 mg/kg/day. These low levels persisted after the fistula was closed and the definitive ileostomy was created. During this 2 year period the patient received cyclosporin in capsule form, there were no rejection episodes and the serum creatinine remained at 130-140 JLIDoIlL.
We assumed that the persistent low CyA levels were due to a combination of: (a) malabsorption caused by a delay in capsular disruption because of gastric hypoacidity; and (b) lack of adequate Ann Clin Biochem 1993: 30 absorptive intestinal surface available following bypass of duodenum and proximal jejunum (at the time of Polya gastrectomy) and resection of a major segment of ileum. The formulation of CyA was, therefore, changed from capsule to a liquid preparation, 5 mg/kg/day. The whole blood CyA levels then increased from < 50 ng/mL to 154 ng/mL within 72 h. Additionally, the ileostomy effluent was collected over 24 h before and after changing the formulations and the CyA loss measured. The capsule was associated with a fourfold increase in CyA ileostomy fluid concentration compared with the liquid formulation, 116'4 against 24·2 mg/L, respectively.
DISCUSSION
The comparable bioavaiiability and pharmacokinetics of CyA oral solution and capsule formulation in a normal individual is well established.v! Drew et al," described an absorption window for CyA in the upper small intestine (duodenum, jejunum and ileum) and suggested that the length of functionally intact proximal small bowel is an important determinant of CyA dosage. Further, they mentioned that oral modified release formulations (i.e. capsules) may have poor absorption if the drug is released beyond the absorption window. 4 The reduced efficiency of CyA absorption in our patient could, therefore, have been due to delayed capsular lysis as a result of gastric hypoacidity. Rapid gastric transit into the jejunum may also have inhibited the capsular disintegration, and bypass of the duodenum and proximal ileum by an intact capsule reduced even further the available absorption length for CyA. The subsequent improved blood CyA concentrations achieved with liquid CyA suggests that this formulation, which does not require gastric acidity for its release, was available for immediate absorption and makes the best use of the reduced absorptive surface available following duodenal and proximal ileal bypass. Newer capsule formulations are, however, being developed to improve absorption by the formation of microemulsions upon contact with digestive juices." Interestingly, during the 12 month period of CyA monotherapy and poor CyA absorption the renal graft remained functioning well. This would suggest that either the graft 'adapted' to the host or that CyA absorption, although low, was sufficient to maintain immunosuppression. However, the suggestion that CyA may become unnecessary with increasing time post transplant is not widely accepted, and it is argued that adequate whole blood CyA concentrations must be maintained. The CyA formulation was therefore changed from capsule to liquid.
As a result of this experience we would advocate the use of a liquid oral CyA preparation in transplant patients who have had ablative or bypass gastric surgery and/or small intestinal loss from fistula or resection, as well as those patients who show consistently low whole blood CyA concentrations with a capsular formulation. This should facilitate the maintenance of adequate blood CyA concentrations in such individuals.
